121 related articles for article (PubMed ID: 23704049)
1. Initial experience with L-leucine therapy in myelodysplastic syndromes with associated chromosome 5q deletion.
Steensma DP; Ebert BL
Blood; 2013 May; 121(21):4428. PubMed ID: 23704049
[No Abstract] [Full Text] [Related]
2. Lenalidomide-mediated erythroid improvement in non-del(5q) myelodysplastic syndromes is associated with bone marrow immuno-remodeling.
Kerdivel G; Chesnais V; Becht E; Toma A; Cagnard N; Dumont F; Rousseau A; Fenaux P; Chevret S; Chapuis N; Boeva V; Fridman WH; Fontenay M; Kosmider O
Leukemia; 2018 Feb; 32(2):558-562. PubMed ID: 28972593
[No Abstract] [Full Text] [Related]
3. Very short-term lenalidomide treatment associated with durable resolution of anemia in a patient with myelodysplastic syndrome with chromosome 5q deletion.
Cannella L; Latagliata R; Breccia M; Carmosino I; Loglisci G; Volpicelli P; Ferretti A; Santopietro M; Vozella F; Girmenia C; Cuzzola M; Oliva EN; Alimena G
Ann Hematol; 2012 Feb; 91(2):309-10. PubMed ID: 21625998
[No Abstract] [Full Text] [Related]
4. Pathophysiology and treatment of the myelodysplastic syndrome with isolated 5q deletion.
Jädersten M
Haematologica; 2010 Mar; 95(3):348-51. PubMed ID: 20207839
[No Abstract] [Full Text] [Related]
5. Haematological and cytogenetic responses after only 7 days of Lenalidomide in a patient with myelodysplastic syndrome and chromosome 5q deletion.
Hadiji Mseddi S; Kallel F; Kassar O; Elloumi M; Jedidi I; Sennana H; Fenaux P
Leuk Res; 2011 Sep; 35(9):e175-6. PubMed ID: 21658768
[No Abstract] [Full Text] [Related]
6. [The 5q- syndrome].
Adès L; Fenaux P
Rev Prat; 2010 Dec; 60(10):1420-2. PubMed ID: 21425544
[No Abstract] [Full Text] [Related]
7. Blood consult: treating del(5q) myelodysplastic syndromes.
Mukherjee S; Tiu RV; Sekeres MA
Blood; 2012 Jan; 119(2):342-4. PubMed ID: 22039258
[No Abstract] [Full Text] [Related]
8. Lenalidomide in del 5q MDS: responses and side effects revisited.
Tiu RV; Sekeres MA
Leuk Res; 2011 Nov; 35(11):1440-1. PubMed ID: 21764127
[No Abstract] [Full Text] [Related]
9. Efficacy of lenalidomide in a patient with myelodysplastic syndrome with isolated del(5q) and JAK2V617F mutation.
Nomdedeu M; Maffioli M; Calvo X; Martínez-Trillos A; Baumann T; Díaz-Beyá M; Aguilar JL; Rozman M; Costa D; Esteve J; Cervantes F; Colomer D; Nomdedeu B
Leuk Res; 2011 Sep; 35(9):1276-8. PubMed ID: 21764129
[No Abstract] [Full Text] [Related]
10. Pleiotropic mechanisms of action of lenalidomide efficacy in del(5q) myelodysplastic syndromes.
Heise C; Carter T; Schafer P; Chopra R
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1663-72. PubMed ID: 20942636
[TBL] [Abstract][Full Text] [Related]
11. Role of lenalidomide in the management of myelodysplastic syndromes with del(5q) associated with pure red cell aplasia (PRCA).
Cerchione C; Catalano L; Cerciello G; Avilia S; Picardi M; Risitano AM; Pisano I; Alfinito F; Pane F
Ann Hematol; 2015 Mar; 94(3):531-4. PubMed ID: 25135452
[No Abstract] [Full Text] [Related]
12. Response to lenalidomide in a patient with myelodysplastic syndrome with isolated del(5q) and JAK2 V617F mutation.
Azaceta G; Calasanz MJ; Dourdil V; Bonafonte E; Izquierdo I; Palomera L
Leuk Lymphoma; 2010 Oct; 51(10):1941-3. PubMed ID: 20846100
[No Abstract] [Full Text] [Related]
13. L-leucine increases translation of
Bello E; Kerry J; Singh S; Yip BH; Kušec R; Killick S; Raynaud S; Boultwood J; Pellagatti A
Haematologica; 2018 Nov; 103(11):e496-e500. PubMed ID: 29903759
[No Abstract] [Full Text] [Related]
14. Multivariate time-dependent comparison of the impact of lenalidomide in lower-risk myelodysplastic syndromes with chromosome 5q deletion.
Sánchez-García J; Del Cañizo C; Lorenzo I; Nomdedeu B; Luño E; de Paz R; Xicoy B; Valcárcel D; Brunet S; Marco-Betes V; García-Pintos M; Osorio S; Tormo M; Bailén A; Cerveró C; Ramos F; Diez-Campelo M; Such E; Arrizabalaga B; Azaceta G; Bargay J; Arilla MJ; Falantes J; Serrano-López J; Sanz GF;
Br J Haematol; 2014 Jul; 166(2):189-201. PubMed ID: 24716538
[TBL] [Abstract][Full Text] [Related]
15. Lenalidomide on alternative days is effective in myelodysplastic syndrome with 5q- deletion.
Defina M; Rondoni M; Gozzetti A; Aprile L; Chitarrelli I; Fabbri A; Lauria F; Bocchia M
Br J Haematol; 2010 Feb; 148(3):483-4. PubMed ID: 19874309
[No Abstract] [Full Text] [Related]
16. Familial occurrence of myelodysplastic syndrome with del(5q).
Volpicelli P; Latagliata R; Carmosino I; Breccia M; Vozella F; Mancini M; Cannella L; Alimena G
Leuk Lymphoma; 2011 Jun; 52(6):1143-5. PubMed ID: 21599595
[No Abstract] [Full Text] [Related]
17. Results of a multicenter prospective phase II trial investigating the safety and efficacy of lenalidomide in patients with myelodysplastic syndromes with isolated del(5q) (LE-MON 5).
Schuler E; Giagounidis A; Haase D; Shirneshan K; Büsche G; Platzbecker U; Nolte F; Götze K; Schlenk RF; Ganser A; Letsch A; Braulke F; Lübbert M; Bug G; Schafhausen P; Bacher U; Gattermann N; Wulfert M; Haas R; Germing U
Leukemia; 2016 Jul; 30(7):1580-2. PubMed ID: 26668126
[No Abstract] [Full Text] [Related]
18. Myelodysplastic syndrome associated with isolated del (5q) chromosome abnormality ("5q- syndrome").
Maslak P
Blood; 2007 Dec; 110(12):3825. PubMed ID: 18062093
[No Abstract] [Full Text] [Related]
19. What lies beyond del(5q) in myelodysplastic syndrome?
Adema V; Bejar R
Haematologica; 2013 Dec; 98(12):1819-21. PubMed ID: 24323981
[No Abstract] [Full Text] [Related]
20. Two different del(5q) clones in a patient with myelodysplastic syndrome.
Braulke F; Schanz J; Steffens R; Liehr T; Manvelyan M; Chudoba I; Haase D
Leuk Lymphoma; 2011 Sep; 52(9):1811-4. PubMed ID: 21657962
[No Abstract] [Full Text] [Related]
[Next] [New Search]
